Lung Cancer Clinical Trials in Philadelphia

Showing 361-380 of 687 trials

Risk Communication in African American Smokers

NCT04084561

The study aims to understand the effects of learning about one's genetic risk for lung cancer that is specific to their ancestry. Participants will be given hypothetical personalized genetic risk results and ask to think about how they might respond to such information if they actually received such results.

Lung Cancer

Temple University166 participantsStarted Sep 2018

New York, New York, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 1< 1 mile

A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518

This is a Phase 1 dose-escalation and confirmation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in participants with advanced solid tumors. The purpose of this study is to define the dosing schedule, and maximally tolerated dose to be used in subsequent development of PRT2527.

SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast Cancer+2 more

Prelude Therapeutics30 participantsStarted Feb 2022

Denver, Colorado, United States • Celebration, Florida, United States • Sarasota, Florida, United States +5 more locations

Risk Communication in African American Smokers

A Study of PRT2527 in Participants With Advanced Solid Tumors

Lung Cancer Trials in Other Cities

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

The Lung Screening, Tobacco and Health Project

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Survival Prolongation by Rationale Innovative Genomics

International Lung Screen Trial (ILST)

Other Conditions in Philadelphia